A large number of nanomolar small-molecule ACACA inhibitors have been developed, and several have been evaluated in clinical trials for metabolic diseases such as obesity and metabolic syndrome [58-60]. This evidence concerns the gene ACACA and obesity due to melanocortin 4 receptor deficiency.